healthy subjects, 19 patients with multiple myeloma (MM) and 21 patients with chronic uremia were given cefodizime (2 g i.v.) at 2 different timepoints either in the morning or in the evening for 5 to 7 consecutive days. The following immunological parameters were comparatively evaluated before and after cefodizime administration: rosette-forming cells (RFC%), T lymphocyte subpopulations, monocyte chemotaxis index (MCI) and granulocyte chemotaxis index (GCI). Independently of the time of drug administration, a circadian rhythm was clearly detected (90% CI) as regards RFC%, CD3, CD4, CD8, CD4/CD8 before and RFC%, CD3, CD4, CD8, GCI after therapy. In addition, in patients treated at 0800 cefodizime increased the MESOR of the MCI and, to a lesser extent, of the GCI. The chronoimmunomodulatory effects of cefodizime in patients with MM and chronic uremia are discussed.
Toward a chronoimmunomodulation by cefodizime in multiple myeloma and chronic uremia / F. Carandente, A. De Vecchi, F. Halberg, G. Cornelissen, F. Dammacco. - In: CHRONOBIOLOGIA. - ISSN 0390-0037. - 15:1-2(1988), pp. 61-85. ((Intervento presentato al convegno Symposia Medica Hoechst : Workshop on Cefodizime tenutosi a Frankfurt am Main nel 1988.
Toward a chronoimmunomodulation by cefodizime in multiple myeloma and chronic uremia
F. CarandentePrimo
;
1988
Abstract
healthy subjects, 19 patients with multiple myeloma (MM) and 21 patients with chronic uremia were given cefodizime (2 g i.v.) at 2 different timepoints either in the morning or in the evening for 5 to 7 consecutive days. The following immunological parameters were comparatively evaluated before and after cefodizime administration: rosette-forming cells (RFC%), T lymphocyte subpopulations, monocyte chemotaxis index (MCI) and granulocyte chemotaxis index (GCI). Independently of the time of drug administration, a circadian rhythm was clearly detected (90% CI) as regards RFC%, CD3, CD4, CD8, CD4/CD8 before and RFC%, CD3, CD4, CD8, GCI after therapy. In addition, in patients treated at 0800 cefodizime increased the MESOR of the MCI and, to a lesser extent, of the GCI. The chronoimmunomodulatory effects of cefodizime in patients with MM and chronic uremia are discussed.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.